Compare Amphastar Pharmaceuticals Inc (AMPH) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Starbucks Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Starbucks Corp trades at $106.52 (market cap $119.30B). The key difference: Starbucks Corp is far larger — about 138.1× Amphastar Pharmaceuticals Inc's market cap, and Starbucks Corp pays a 2.37% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SBUX | |
|---|---|---|
Market Cap | $863.95M | $119.30B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $108.37 |
52-Week Low | $16.87 | $78.46 |
Enterprise Value | $1.26B | $138.12B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Starbucks (SBUX) trades at $105.58, up 0.4% today, with a bullish technical signal and recent earnings beats driving momentum. The stock shows strong fundamental recovery with Q2 2026 EPS of $0.85 beating estimates by 29%, while revenue growth and margin expansion support a raised 2026 outlook. Analyst consensus is split evenly between Buy and Hold, with a $113.60 price target suggesting modest upside from current levels.
The outlook is positive as operational improvements and traffic recovery underpin earnings growth, but high valuation multiples (P/E 61) and competitive pressures pose risks. Investor sentiment is cautiously optimistic, focusing on sustained execution of the turnaround strategy amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
